Oncology
focused pharmaceutical development company Kiadis Pharma announced
that it has successfully completed a Phase II clinical trial evaluating its
product Reviroc(TM). Reviroc is used to eliminate cancer cells from an
autologous graft in bone marrow transplantations for end stage blood cancer
patients. Data from the clinical study revealed improved overall survival
of Reviroc-treated patients. The successful completion of the clinical
trial allows Kiadis Pharma to prepare for a Phase III clinical study.
Manja Bouman, CEO, Kiadis Pharma, comments: "We are obviously very
pleased with the completion of this Phase II trial of Reviroc. It brings
treatment with our product a step closer to patients with end stage blood
cancer. Reviroc shares its development platform with two other Kiadis
Pharma products: ATIR and Rhitol. The results of this trial therefore mark
an important milestone in the development of our entire clinical product
pipeline."
In the non-randomized open label study 25 patients, each of whom had
reached end stage Non-Hodgkin's lymphoma, were treated in multiple centers
in Canada. The objective of the study was to determine the safety of the
Reviroc treatment and its ability to eliminate cancer cells from a
contaminated graft. Reviroc-treated grafts all showed excellent
engraftment, indicating that Reviroc does not negatively impact the graft
itself.
The Reviroc clinical trial data was evaluated against a historical
patient control group from the Center for International Blood and Marrow
Transplant Research (CIBMTR). The results for Reviroc-treated patients were
compared with results from the CIBMTR database for patients who had
received an autologous transplant without Reviroc. The outcome of this
comparison shows that the Reviroc-treated patient group had an 80% chance
of survival at 3 years post transplantation, while the CIBMTR control group
had a 55% chance of survival at 3 years post transplantation. Based on
these promising data, Kiadis Pharma will prepare for a clinical phase III
study of Reviroc.
Dr. Denis-Claude Roy at Maisonneuve-Rosemont Hospital in Montreal,
commented: "After more then five years of clinical research, we believe
that our results demonstrate that Reviroc is able to improve patient
survival. This is potentially a breakthrough achievement for patients
suffering from Non-Hodgkin's lymphoma as well as their families."
About Reviroc
Reviroc is being developed as a treatment that eliminates blood cancer
cells from autologous transplants for patients with end stage blood cancer.
An autologous transplant uses the patient's own bone marrow to serve as a
graft. Bone marrow transplantations are broadly recognized as a treatment
option for patients suffering from blood cancers, such as leukemia and
lymphoma. Reviroc has been developed to remove residual tumor cells from
the graft.
About Kiadis Pharma
Kiadis Pharma is an oncology focused pharmaceutical development company
with four products in different phases of clinical development. The company
develops products that offer novel treatment options for terminally ill
cancer patients and address high unmet medical needs. Key areas for Kiadis
Pharma are clinical indications in blood cancers and solid tumors. Kiadis
Pharma is headquartered in the Netherlands with facilities in Groningen,
the Netherlands and Montreal, Canada. For more information about Kiadis
Pharma, please visit kiadis
Kiadis Pharma
kiadis